“Fake Advertising”: Allergan Should Be Red in the Face for Using “Before & After”...
Allergan is again resorting to side-by-side "before and after” images in a drug ad to prove that Rhofade - its new drug for the...
PinUp: Fake Advertising – Is It a Thing Now for Big Pharma Marketers?
Welcome to the August 8, 2017, issue of Pharma Industry News Update (aka PinUp). I'm always on the lookout for misleading drug ads. Recently, however, I've become aware of 'fake advertising' by pharma marketers. We've all seen fake ads in weight loss commercials that use retouched photos to gain competitive advantage. But mainstream
PinUp: Educating physicians and patients about today’s newfangled drugs is fraught with challenges &...
Welcome to the August 4, 2017, issue of Pharma Industry News Update (aka PinUp). Educating physicians and patients about today's newfangled drugs is fraught with 'challenges and potential pitfalls.' The situation is exacerbated by the Internet, which competes with the information that the drug industry wishes to promulgate.
PinUp: Pharma Scientists Mad at Hollywood, But They Also Should Be Mad at Hackers...
Welcome to the August 1, 2017, issue of Pharma Industry News Update (aka PinUp). Pharma scientists may be concerned about the portrayal of biopharma scientists as crazed villains in Hollywood movies, but they should be more concerned - mad as hell - about clinical and other data being hacked especially since their IT people should have been more on the ball!
PinUp: Celgene Settles Off-Label Suit, FDA Makes “PEACe” with Patients & Looks for Digital...
Welcome to the July 28, 2017, issue of Pharma Industry News Update (aka PinUp). The Celgene case raises an interesting pharma marketing/regulatory issue; namely, are Medical Science Liaisons being deployed by pharma as sales reps in disguise in order to market drugs off-label? Meanwhile, FDA is looking to
PinUp: Abbvie misleads while AZ, Lilly, GSK engage. All are lobbying energetically!
Welcome to the July 25, 2017, issue of Pharma Industry News Update (aka PinUp). False and misleading drug advertising is usually the bailiwick of the FDA. But when the FDA fails to act - and even when it does - there's always litigation. An example is the recent federal court decision to award a plaintiff $150 million for punitive damages due to
PinUp: Computer Modeling at FDA, Periodic Table of Pharma Multi-Channel Marketing, more…
Welcome to the July 21, 2017, issue of Pharma Industry News Update (aka PinUp). Computers may help the FDA speed up drug approval, and there may be many channels for pharma to reach out to patients, but some patients - especially women patients - still are not very confident that they know enough about their chronic medical conditions.
PinUp: Pharma Sponsored CME Inches Forward, “Bribe to Prescribe”, more…
Welcome to the July 18, 2017, issue of Pharma Industry News Update (aka PinUp). Pharma has been leery of sponsoring accredited CME programs for years for various reasons. But the industry still likes to host 'speaker programs' to educate physicians without accreditation. Some of these programs, however, are nothing more than 'bribe to prescribe' events.
PinUp: Who Was the Highest Paid Pharma Executive in 2016? more…
Welcome to the July 14, 2017, issue of Pharma Industry News Update (aka PinUp). It's time to see which pharma executives received the most compensation in 2016, even if a large chunk depends on stock price! We're talking tens of millions of dollars here! I am totally surprised that Pfizer's CEO and Chairman Ian Read 'took home' so much less than 'price gouging' Mylan and Valeant executives. Go figure!
PinUp: Funding of Digital Health “Moonshots,” more…
Welcome to the July 11, 2017, issue of Pharma Industry News Update (aka PinUp). Investors - including many pharmaceutical companies - are pouring billions of dollars into digital health companies. Many of the 'solutions' offered by these companies will never see the light of day. One expert - Richard Meyer, Principal at Strategic Marketing Solutions - believes 'most of the money will never see dime one of ROI.'


















